Fosun Kite's CAR-T Approved in China for Lymphoma

Fosun Kite Biotech, a Shanghai JV set up to develop Kite's CAR-T therapy in China , reported Yescarta (axicabtagene ciloleucel) was approved to treat relapsed or refractory large B-cell lymphoma. Yescarta is the first CAR-T therapy allowed to launch in China . The approval was for third-line treatment. Axicabtagene ciloleucel is an autologous CD19-directed CAR T-cell therapy manufactured in China under a license from Kite. To acquire 50% of the JV, Fosun Pharma agreed to a $95 million package that will entitle it to receive 60% of the profits. More details.... Share this with colleagues: // //